PMID- 15988908
OWN - NLM
STAT- MEDLINE
DCOM- 20051003
LR  - 20071115
IS  - 1472-4472 (Print)
IS  - 1472-4472 (Linking)
VI  - 6
IP  - 6
DP  - 2005 Jun
TI  - Priming anticancer active specific immunotherapy with dendritic cells.
PG  - 576-81
AB  - Dendritic cells (DCs) probably represent the most powerful naturally occurring 
      immunological adjuvant for anticancer vaccines. However, the initial enthusiasm 
      for DC-based vaccines is being tempered by clinical results not meeting 
      expectations. The partial failure of current vaccine formulations is explained by 
      the extraordinary complexity of the immune system, which makes the task of 
      exploiting the potential of such a biotherapeutic approach highly challenging. 
      Clinical findings obtained in humans so far indicate that the immune system can 
      be actively polarized against malignant cells by means of DC-based active 
      specific immunotherapy, and that in some cases this is associated with tumor 
      regression. This implies that under some unique circumstances, the naturally 
      'dormant' immune effectors can actually be employed as endogenous weapons against 
      malignant cells. Only the thorough understanding of DC biology and tumor-host 
      immune system interactions will allow researchers to reproduce, in a larger set 
      of patients, the cellular/molecular conditions leading to an effective 
      immune-mediated eradication of cancer.
FAU - Mocellin, Simone
AU  - Mocellin S
AD  - Department of Oncological & Surgical Sciences, University of Padova, via 
      Giustiniani 2, 35128 Padova, Italy. simone.mocellins@unipd.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy, Active/*methods
MH  - Neoplasms/immunology/*therapy
RF  - 74
EDAT- 2005/07/02 09:00
MHDA- 2005/10/04 09:00
CRDT- 2005/07/02 09:00
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/10/04 09:00 [medline]
PHST- 2005/07/02 09:00 [entrez]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2005 Jun;6(6):576-81.